Health Economics›Peripheral T-cell lymphoma›Untreated non-randomized or retrospective data

Untreated non-randomized or retrospective data

Peripheral T-cell lymphoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
A-CHOP Variant #01	—	R 122 714	28d	—	—	~8	~R 276 011 indirect	—
CHOP and Everolimus Variant #01	—	R 5 631	21d	—	—	~6	~R 33 788 indirect	—
DA-EPOCH Variant #01	—	R 2 155	21d	—	—	~8	~R 17 240 indirect	—
CHOEP-14 Variant #01	—	R 2 109	14d	—	—	~6	~R 12 655 indirect	—
DD-CHOP Variant #01 Partial	—	R 1 041	21d	—	—	~8	~R 8 332 indirect	—
HyperCHidam Variant #01	—	R 203	—	—	—	~2	~R 406 indirect	—

6 of 6 regimens shown